NKTR vs VFC · rev $21.0M vs P/E 26, rev $9.61B
Nektar Therapeutics (NKTR) versus VF Corporation (VFC) — a side-by-side from cached financials, not a winner call.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
VF Corporation (VFC) is a apparel manufacturing company listed on NYSE.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
Latest reported VFC revenue for 2026-03-28 was $9.61B. Net income was $254.9M. Revenue was up 1.1% from 2025-03-29 to 2026-03-28. VFC currently screens at market cap $6.55B and trailing P/E 26.1.
NKTR currently screens at market cap $307.2M. VFC currently screens at market cap $6.55B and trailing P/E 26.1.
Not investment advice. Open the NKTR and VFC stock pages for the full models.
Not investment advice.